Allied Corp
OTC:ALID
Allied Corp
Total Equity
Allied Corp
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Allied Corp
OTC:ALID
|
Total Equity
-$7.6m
|
CAGR 3-Years
-209%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Total Equity
-$554m
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Canopy Growth Corp
TSX:WEED
|
Total Equity
CA$758.2m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
19%
|
|
|
Cronos Group Inc
TSX:CRON
|
Total Equity
$1.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
63%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Total Equity
$130.6m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
46%
|
CAGR 10-Years
84%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Total Equity
CA$766.8m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
Allied Corp
Glance View
Allied Corp. operates as a medical cannabis company. The company is headquartered in Kelowna, British Columbia. The company went IPO on 2018-12-04. The firm is focused on creating and providing health solutions to address medical mental health issues. The firm focuses to discover medical technologies, which are cannabis derived to target full scope therapy and support for trauma survivors, military veterans and first responders. Its functional mushroom formulation targets major depression and anxiety. The firm is also engaged in research and development activities in the psilocybin space and holds formulations.
See Also
What is Allied Corp's Total Equity?
Total Equity
-7.6m
USD
Based on the financial report for Nov 30, 2024, Allied Corp's Total Equity amounts to -7.6m USD.
What is Allied Corp's Total Equity growth rate?
Total Equity CAGR 3Y
-209%
Over the last year, the Total Equity growth was -5%. The average annual Total Equity growth rates for Allied Corp have been -209% over the past three years .
